No profile data available.
RedHill Biopharma Ltd. (RDHL) is a healthcare company in the antibacterial pharmaceuticals industry, based in Tel Aviv-Yafo, Israel, with about 13 full-time employees.
It reported revenue of $286,000 for fiscal year 2025, down 96.4% from fiscal year 2024, and net income of -$429,000. U.S. was its largest region in fiscal year 2024, with 93% of revenue. Its market capitalization was $4.79 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
RedHill Biopharma reported $286,000 in revenue for fiscal year 2025, down 96.4% from $8.04 million in fiscal year 2024.
U.S.: 93% of revenue by region in fiscal year 2024, followed by United Arab Emirates (7%).
$4.79 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antibacterial pharmaceuticals) include Seres Therapeutics, Inc. (MCRB), Acurx Pharmaceuticals, Inc. (ACXP), BiomX Inc. (PHGE), ViaDerma, Inc. (VDRM).